GLS1 Human Recombinant

<strong>GLS1 Human Recombinant </strong>_x000D_ <strong>Catalog number:</strong> B2016869_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 20 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 73 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -80°C_x000D_ <strong>Keywords:</strong> GAC, GAM, GLS, K-glutaminase, Glutaminase Kidney Isoform Mitochondrial, Glutaminase Transcript Variant 1, KGA ,L-glutamine Amidohydrolase_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Jo M, Koizumi K, Suzuki M, Kanayama D, Watanabe Y, Gouda H, Mori H, Mizuguchi M, Obita T, Nabeshima Y, Toyooka N, Okada T. Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors Bioorg Med Chem Lett. 2023 May 1;87:129266._x000D_ 2: Cederkvist H, Kolan SS, Wik JA, Sener Z, Skålhegg BS. Identification and characterization of a novel glutaminase inhibitor FEBS Open Bio. 2022 Jan;12(1):163-174._x000D_ 3: DeLaBarre B, Gross S, Fang C, Gao Y, Jha A, Jiang F, Song J J, Wei W, Hurov JB. Full-length human glutaminase in complex with an allosteric inhibitor Biochemistry. 2011 Dec 20;50(50):10764-70._x000D_ 4: Hartwick EW, Curthoys NP. BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase J Enzyme Inhib Med Chem. 2012 Dec;27(6):861-7._x000D_ 5: Feng Y, Pathria G, Heynen-Genel S, Jackson M, James B, Yin J, Scott DA, Ronai ZA. Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma Mol Cancer Ther. 2021 May;20(5):816-832._x000D_ 6: Soth MJ, Le K, Di Francesco ME, Hamilton MM, Liu G, Burke JP, Carroll CL, Kovacs JJ, Bardenhagen JP, Bristow CA, Cardozo M, Czako B, de Stanchina E, Feng N, Garvey JR, Gay JP, Do MKG, Greer J, Han M, Harris A, Herrera Z, Huang S, Giuliani V, Jiang Y, Johnson SB, Johnson TA, Kang Z, Leonard PG, Liu Z, McAfoos T, Miller M, Morlacchi P, Mullinax RA, Palmer WS, Pang J, Rogers N, Rudin CM, Shepard HE, Spencer ND, Theroff J, Wu Q, Xu A, Yau JA, Draetta G, Toniatti C, Heffernan TP, Jones P. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties J Med Chem. 2020 Nov 12;63(21):12957-12977._x000D_ 7: Xu X, Li J, Sun X, Guo Y, Chu D, Wei L, Li X, Yang G, Liu X, Yao L, Zhang J, Shen L. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression Oncotarget. 2015 Sep 22;6(28):26161-76._x000D_ 8: Xia X, Cao G, Sun G, Zhu L, Tian Y, Song Y, Guo C, Wang X, Zhong J, Zhou W, Li P, Zhang H, Hao J, Li Z, Deng L, Yin Z, Gao Y. GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis J Clin Invest. 2020 Oct 1;130(10):5180-5196._x000D_ 9: Jiang B, Zhang J, Zhao G, Liu M, Hu J, Lin F, Wang J, Zhao W, Ma H, Zhang C, Wu C, Yao L, Liu Q, Chen X, Cao Y, Zheng Y, Zhang C, Han A, Lin D, Li Q. Filamentous GLS1 promotes ROS-induced apoptosis upon glutamine deprivation via insufficient asparagine synthesis Mol Cell. 2022 May 19;82(10):1821-1835.e6._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/34023970">10: Yu W, Yang X, Zhang Q, Sun L, Yuan S, Xin Y. Targeting GLS1 to cancer therapy through glutamine metabolism Clin Transl Oncol. 2021 Nov;23(11):2253-2268. </a>_x000D_ _x000D_ <strong>Products Related to GLS1 Human Recombinant can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>